Autopsy report · NCT03002103

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“study design reconsideration”

The sponsor’s own words in the registry.

Life of this trial

Suspended: paused, and may or may not restart.
420 participants planned (an estimate, not an actual count).

Vital statistics

Status: Suspended
Phase: Phase 3
Sponsor: SynCore Biotechnology Co., Ltd.
Sponsor type: Industry
Conditions: Triple-Negative Breast Cancer
Interventions: EndoTAG-1; Paclitaxel; Gemcitabine Hydrochloride
Participants: 420 (planned, not actual)
Sites: 6
Countries: Taiwan

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.